BERGENBIO
Summary
BerGenBio is a Norwegian clinical-stage biopharmaceutical company focused on developing AXL kinase inhibitors, primarily the lead candidate bemcentinib, to treat aggressive diseases like drug-resistant cancers and severe respiratory infections.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 12 M
Avg. Deal Size£ 12 M
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite
